CS-917, a fructose 1,6-bisphosphatase inhibitor, reduces plasma glucose by suppressing hepatic glucose production, whereas metformin stimulates gastrointestinal glucose uptake

被引：0

作者：

Okuno, A. ^{[1
]}

Tanaka, J. ^{[1
]}

Takahashi, K. ^{[1
]}

Ogawa, J. ^{[1
]}

Hagisawa, Y. ^{[1
]}

Kanda, S. ^{[1
]}

Yoshida, T. ^{[1
]}

机构：

[1] Daiichi Sankyo Co Ltd, Biol Res Labs 2, Tokyo, Japan

来源：

DIABETOLOGIA | 2007年 / 50卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0218

引用

页码：S95 / S95

页数：1

共 39 条

[1] Comparative effects of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin
Okuno, A.
Yoshida, T.
Tanaka, J.
Takahashi, K.
Kanda, S.
Nakashima, R.
Ogawa, J.
Hagisawa, Y.
DIABETOLOGIA, 2006, 49 : 132 - 132
[2] CS-917, a fructose 1,6-bisphosphatase inhibitor, combined with a thiazolidinedione or insulin decreases plasma glucose and improves lactate metabolism more effectively than CS-917 monotherapy
Yoshida, T.
Ogawa, J.
Hagisawa, Y.
Kanda, S.
Takahashi, K.
Okuno, A.
DIABETOLOGIA, 2007, 50 : S375 - S375
[3] CS-917, a fructose 1,6-bisphosphatase inhibitor, suppresses gluconeogenesis in human hepatocytes, whereas metformin stimulates glycolysis in Caco-2 cells
Okuno, Akira
Takahashi, Kanako
Tanaka, Jun
Yoshida, Taishi
DIABETES, 2007, 56 : A130 - A130
[4] Comparison of acute and chronic glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin, in rat models of type 2 diabetes
Yoshida, Taishi
Takahashi, Kanako
Nakashima, Ryutaro
Kanda, Shoichi
Okuno, Akira
DIABETES, 2006, 55 : A139 - A139
[5] Initial safety, tolerability and glucose lowering of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes
Bruce, S. R.
Walker, J.
Feins, K.
Tao, B.
Triscari, J.
DIABETOLOGIA, 2006, 49 : 25 - 25
[6] CS-917, a fructose 1,6-bisphosphatase inhibitor, suppresses gluconeogenesis in vitro and in vivo by a different mechanism than metformin
Okuno, Akira
Tanaka, Jun
Takahashi, Kanako
Nakashima, Ryutaro
Kanda, Shoichi
Ogawa, Junko
Hagisawa, Yuka
Yoshida, Taishi
DIABETES, 2006, 55 : A128 - A129
[7] CS-917, a fructose 1,6-bisphosphatase inhibitor, has glucose-lowering effects in cynomolgus monkeys and improves postprandial hyperglycemia in goto-kakizaki (GK) rats
Yoshida, T
Izumi, M
Takahashi, K
Hagisawa, Y
Ohsumi, J
Fujiwara, T
Okuno, A
DIABETES, 2005, 54 : A116 - A117
[8] Contributions of Hepatic Gluconeogenesis Suppression and Compensative Glycogenolysis on the Glucose-Lowering Effect of CS-917, a Fructose 1,6-Bisphosphatase Inhibitor, in Non-obese Type 2 Diabetes Goto-Kakizaki Rats
Yoshida, Taishi
Okuno, Akira
Takahashi, Kanako
Ogawa, Junko
Hagisawa, Yuka
Kanda, Shoichi
Fujiwara, Toshihiko
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (03) : 329 - 335
[9] MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
Erion, MD
van Poelje, PD
Dang, Q
Kasibhatla, SR
Potter, SC
Reddy, MR
Reddy, KR
Jiang, T
Lipscomb, WN
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (22) : 7970 - 7975
[10] Enhancement of insulin signaling suppresses lactate elevation induced by CS-917, a fructose 1,6-bisphosphatase (F1,6-BPase) inhibitor
Yoshida, Taishi
Ogawa, Junko
Hagisawa, Yuka
Kanda, Shoichi
Takahashi, Kanako
Okuno, Akira
DIABETES, 2007, 56 : A131 - A131

← 1 2 3 4 →